Extensive functional studies have indicated that decreased of MEG3 occurs in many of human tumors and tumor derived cell lines, strongly suggesting that MEG3 inhibitors cancer progression (Greife et al., 2014; Li Z.H. et al., 2017; Terashima et al., 2017; Zhang J. et al., 2017). This evidence concerns the gene MEG3 and cancer.